骨肿瘤的分子与转化研究。
Molecular and Translational Research on Bone Tumors.
机构信息
Bone Physiopathology Research Unit, Translational Pediatrics and Clinical Genetics Research Division, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
出版信息
Int J Mol Sci. 2023 Jan 18;24(3):1946. doi: 10.3390/ijms24031946.
Abstract
Primary bone tumors (PBTs) represent a huge variety of rare malignancies that originate in the skeletal system [...].
摘要
原发性骨肿瘤（PBTs）是一类起源于骨骼系统的罕见恶性肿瘤，种类繁多[... ]。
相似文献
1
Molecular and Translational Research on Bone Tumors.骨肿瘤的分子与转化研究。
Int J Mol Sci. 2023 Jan 18;24(3):1946. doi: 10.3390/ijms24031946.
2
[Bone tumors].[骨肿瘤]
Verh Dtsch Ges Pathol. 2007;91:83-6.
3
[Cytogenetic and molecular genetic changes in malignant primary bone tumors].[恶性原发性骨肿瘤的细胞遗传学和分子遗传学改变]
Radiologe. 1998 Jun;38(6):467-71. doi: 10.1007/s001170050381.
4
Primary malignant bone tumors--recent developments.原发性骨恶性肿瘤——最新进展。
Semin Diagn Pathol. 2011 Feb;28(1):86-101. doi: 10.1053/j.semdp.2011.02.002.
5
[Hereditary bone tumors].[遗传性骨肿瘤]
Pathologe. 2017 May;38(3):179-185. doi: 10.1007/s00292-017-0284-y.
6
Molecular pathology and its diagnostic use in bone tumors.分子病理学及其在骨肿瘤诊断中的应用
Cancer Genet. 2012 May;205(5):193-204. doi: 10.1016/j.cancergen.2012.04.001.
7
Molecular Pathology of Bone Tumors: What Have We Learned and How Does It Affect Daily Practice?骨肿瘤的分子病理学：我们学到了什么以及它如何影响日常实践？
Surg Pathol Clin. 2017 Sep;10(3):xiii-xiv. doi: 10.1016/j.path.2017.06.001.
8
Tumor bone diseases: molecular mechanisms and opportunities for novel treatments.肿瘤骨疾病：分子机制与新型治疗机遇
Curr Med Chem Anticancer Agents. 2001 Nov;1(3):313-29. doi: 10.2174/1568011013354589.
9
Deep learning-based diagnostic models for bone lesions: is current research ready for clinical translation?基于深度学习的骨病变诊断模型：当前研究是否已准备好用于临床转化？
Eur Radiol. 2024 Jul;34(7):4284-4286. doi: 10.1007/s00330-023-10555-w. Epub 2024 Jan 8.
10
Skeletal and extraskeletal myxoid chondrosarcoma: related or distinct tumors?骨内和骨外黏液样软骨肉瘤：相关还是不同的肿瘤？
Adv Anat Pathol. 1999 Jul;6(4):204-12.
引用本文的文献
1
Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1.尿石素A通过靶向基质金属蛋白酶（MMPs）和蛋白激酶B1（AKT1）抑制骨肉瘤细胞的迁移和侵袭。
Sci Rep. 2025 Jul 17;15(1):25941. doi: 10.1038/s41598-025-11804-2.
2
7-Geranyloxycoumarin modulated metastatic potential of osteosarcoma cells via interaction with MMPs and JAK1/2.7-香叶氧基香豆素通过与基质金属蛋白酶和JAK1/2相互作用调节骨肉瘤细胞的转移潜能。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 15. doi: 10.1007/s00210-025-03847-z.
3
Lesson on obesity and anatomy of adipose tissue: new models of study in the era of clinical and translational research.肥胖与脂肪组织解剖学课程：临床与转化研究时代的新研究模型。
J Transl Med. 2024 Aug 14;22(1):764. doi: 10.1186/s12967-024-05547-3.
4
Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma.酪氨酸蛋白激酶MET在骨肉瘤中的治疗潜力
Front Mol Biosci. 2024 Mar 26;11:1367331. doi: 10.3389/fmolb.2024.1367331. eCollection 2024.
5
Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations.揭示褪黑素在骨肉瘤中的保护作用：当前的认识和局限性。
Biomolecules. 2024 Jan 24;14(2):145. doi: 10.3390/biom14020145.
6
Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma.工程化生物材料递送策略用于降低骨肉瘤中的心脏毒性。
Front Pharmacol. 2023 Oct 3;14:1284406. doi: 10.3389/fphar.2023.1284406. eCollection 2023.
7
Advances in Osteosarcoma.骨肉瘤的研究进展。
Curr Osteoporos Rep. 2023 Aug;21(4):330-343. doi: 10.1007/s11914-023-00803-9. Epub 2023 Jun 17.
本文引用的文献
1
CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.CD44 有助于调节骨肉瘤中 MDR1 蛋白和多柔比星化疗耐药性。
Int J Mol Sci. 2022 Aug 3;23(15):8616. doi: 10.3390/ijms23158616.
2
Analyzing BMP2, FGFR, and TGF Beta Expressions in High-Grade Osteosarcoma Untreated and Treated Autografts Using Proteomic Analysis.采用蛋白质组学分析方法分析未治疗和治疗的高级骨肉瘤自体移植物中 BMP2、FGFR 和 TGFβ 的表达。
Int J Mol Sci. 2022 Jul 3;23(13):7409. doi: 10.3390/ijms23137409.
3
New Borane-Protected Derivatives of α-Aminophosphonous Acid as Anti-Osteosarcoma Agents: ADME Analysis and Molecular Modeling, In Vitro Studies on Anti-Cancer Activities, and NEP Inhibition as a Possible Mechanism of Anti-Proliferative Activity.新型硼烷保护的α-氨基膦酸衍生物作为骨肉瘤治疗药物：ADME 分析和分子建模、体外抗癌活性研究以及 NEP 抑制作为抗增殖活性的可能机制。
Int J Mol Sci. 2022 Jun 16;23(12):6716. doi: 10.3390/ijms23126716.
4
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.转移性骨肉瘤治疗的最新和正在进行的研究。
Int J Mol Sci. 2022 Mar 30;23(7):3817. doi: 10.3390/ijms23073817.
5
Challenges of Systemic Therapy Investigations for Bone Sarcomas.骨肉瘤系统治疗研究的挑战。
Int J Mol Sci. 2022 Mar 24;23(7):3540. doi: 10.3390/ijms23073540.
6
Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.犬组织外泌体的蛋白质组学评估作为一种鉴定骨肉瘤分子靶点的方法：PSMD14/Rpn11 作为原理验证。
Int J Mol Sci. 2022 Mar 17;23(6):3256. doi: 10.3390/ijms23063256.
7
Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?骨肿瘤细胞外囊泡：拮抗剂还是治疗剂？
Int J Mol Sci. 2021 Nov 22;22(22):12586. doi: 10.3390/ijms222212586.
8
15d-PGJ Promotes ROS-Dependent Activation of MAPK-Induced Early Apoptosis in Osteosarcoma Cell In Vitro and in an Ex Ovo CAM Assay.15d-PGJ 通过促进 ROS 依赖性 MAPK 诱导的早期细胞凋亡促进骨肉瘤细胞体外和鸡胚尿囊膜测定中的凋亡。
Int J Mol Sci. 2021 Oct 29;22(21):11760. doi: 10.3390/ijms222111760.
9
Benign Bone-Forming Tumors.良性成骨肿瘤。
Surg Pathol Clin. 2021 Dec;14(4):549-565. doi: 10.1016/j.path.2021.06.002. Epub 2021 Oct 7.
10
Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.抑制雌激素受体α抑制 P53 阳性 U2OS 骨肉瘤细胞的增殖、分化并增强其化疗敏感性。
Int J Mol Sci. 2021 Oct 18;22(20):11238. doi: 10.3390/ijms222011238.
Zotero 插件